Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Veru Inc. - SIC # 2840 -
Ticker
Exchange
SIC #
Website
Latest Ticker
VERU
Nasdaq
2840
verupharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Veru Inc.
Veru to Present Two Abstracts at ObesityWeek 2025
- Oct 31st, 2025 6:30 am
Veru Announces Pricing of $25 Million Public Offering
- Oct 30th, 2025 6:00 am
Veru Announces Proposed Public Offering
- Oct 29th, 2025 2:01 pm
October 2025's Noteworthy Penny Stocks
- Oct 8th, 2025 12:05 pm
Onconetix announces financing through private placement, debt settlement
- Sep 27th, 2025 6:40 am
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
- Sep 26th, 2025 6:30 am
Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity
- Sep 23rd, 2025 6:30 am
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm
- Aug 15th, 2025 7:20 am
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
- Aug 12th, 2025 4:30 am
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology
- Aug 11th, 2025 2:01 pm
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study
- Aug 11th, 2025 6:30 am
Veru Announces Reverse Stock Split
- Aug 6th, 2025 6:30 am
Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th
- Aug 5th, 2025 6:30 am
Veru to Participate in the 2025 BTIG Virtual Biotech Conference
- Jul 22nd, 2025 6:30 am
Veru And Two Other Penny Stocks To Consider
- Jun 26th, 2025 12:05 pm
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
- Jun 24th, 2025 6:30 am
One Veru Insider Raised Stake By 150% In Previous Year
- Jun 22nd, 2025 6:28 am
Veru to Participate in the Virtual BTIG Obesity Health Forum
- Jun 11th, 2025 6:30 am
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
- May 28th, 2025 4:30 am
Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial ...
- May 9th, 2025 1:08 am
Scroll